Influenza vaccines: An Asia-Pacific perspective

Influenza and other Respiratory Viruses

Volumn 7, Issue SUPPL.3, 2013, Pages 44-51

  Jennings, Lance C ^a,b  

^a CANTERBURY HEALTH LABORATORIES   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

APACI; Influenza; Pandemic; Seasonal; Vaccine advocacy; Vaccine strategies

Indexed keywords

EPITOPE; GLYCOPROTEIN; INACTIVATED VACCINE; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

2009 H1N1 INFLUENZA; ABSENTEEISM; ASIA; AUSTRALIA; BANGLADESH; CELL CULTURE; CHINA; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; ELDERLY CARE; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; HUMORAL IMMUNITY; INDIA; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; JAPAN; LAOS; MALI; MORTALITY; NEPAL; NONHUMAN; PANDEMIC INFLUENZA; PAPUA NEW GUINEA; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; REIMBURSEMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEASONAL INFLUENZA; SEVERE ACUTE RESPIRATORY SYNDROME; SOUTH KOREA; TECHNOLOGY; VACCINE PRODUCTION; VIET NAM; WORLD HEALTH ORGANIZATION;

APACI; INFLUENZA; PANDEMIC; SEASONAL; VACCINE ADVOCACY; VACCINE STRATEGIES;

ASIA; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; PACIFIC ISLANDS;

EID: 84887566166     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12180     Document Type: Review

References (85)

1. Viboud C, Alonso WJ, Simonsen L. Influenza in tropical regions. PLoS Med 2006; 3:e89.
2. Jennings LC, Smith DW, Chan PK. Report of the first Asia-Pacific influenza summit, Asia-Pacific Alliance for the Control of Influenza (APACI), Bangkok, 12-13 June 2012. Influenza Other Respi Viruses. 2013; doi: 10.1111/irv.12133.
3. Gupta V, Dawood FS, Muangchana C et al. Influenza vaccination guidelines and vaccine sales in southeast Asia: 2008-2011. PLoS ONE 2012; 7:e52842.
4. Members of the Western Pacific Regional Global Influenza Surveillance and Response System. Seasonal influenza vaccine policies, recommendations and use in the World Health Organization's Western Pacific Region. WPSAR 2013; 4:1-9.
5. Samaan G, McPherson M, Partridge J. A review of the evidence to support influenza vaccine introduction in countries and areas of WHO's Western Pacific Region. PLoS ONE 2013; 8:e70003.
6. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-186.
7. Chow A, Ma S, Ling AE, Chew SK. Influenza-associated deaths in tropical Singapore. Emerg Infect Dis 2006; 12:114-121.
8. Wong CM, Chan KP, Hedley AJ, Peiris JS. Influenza-associated mortality in Hong Kong. Clin Infect Dis 2004; 39:1611-1617.
9. Li CK, Choi BC, Wong TW. Influenza-related deaths and hospitalizations in Hong Kong: a subtropical area. Public Health 2006; 120:517-524.
10. Feng L, Shay DK, Jiang Y et al. Influenza-associated mortality in temperate and subtropical Chinese cities, 2003-2008. Bull World Health Organ 2012; 90:279-288B.
11. Western Pacific Region Global Influenza Surveillance and Response System. Epidemiological and virological characteristics of influenza in the Western Pacific Region of the World Health Organization, 2006-2010. PLoS ONE 2012; 7:e37568.
12. Partridge J, Kieny MP. Global production capacity of seasonal influenza vaccine in 2011. Vaccine 2013; 31:728-731.
13. WHO. Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec 2012; 87:461-476.
14. Shortridge KF, Stuart-Harris CH. An influenza epicentre? Lancet 1982; 2:812-813.
15. Russell CA, Jones TC, Barr IG et al. The global circulation of seasonal influenza A (H3N2) viruses. Science 2008; 320:340-346.
16. Jones KE, Patel NG, Levy MA et al. Global trends in emerging infectious diseases. Nature 2008; 451:990-993.
17. Webby RJ, Webster RG. Are we ready for pandemic influenza? Science 2003; 302:1519-1522.
18. Gao R, Cao B, Hu Y et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-1897.
19. WHO. Global Action Plan for Influenza Vaccines 2011. Available at http://www.who.int/influenza_vaccines_plan/en/ (Accessed 20 August 2013).
20. WHO. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2012 - conclusions and recommendations. Wkly Epidemiol Rec 2012; 87(21):201-206.
21. Suhardono M. Establishment of pandemic influenza vaccine production capacity at Bio Farma, Indonesia. Vaccine 2011; 29(Suppl. 1):A22-A25.
22. Surichan S, Wirachwong P, Supachaturas W et al. Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: addressing the threat of an influenza pandemic. Vaccine 2011; 29(Suppl 1):A29-A33.
23. Ventura R, Brunner L, Heriyanto B et al. Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia. Vaccine 2013; 31:1641-1645.
24. Friede M, Palkonyay L, Alfonso C et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011; 29(Suppl 1):A2-A7.
25. Hoa LK, Hiep LV, Be LV. Development of pandemic influenza vaccine production capacity in Viet Nam. Vaccine 2011; 29(Suppl 1):A34-A36.
26. Hossain S. Lessons learnt from pandemic influenza vaccine deployment and vaccination. First meeting on seasonal influenza vaccines in the Western Pacific Region, Manilla, 22-23 October, 2012.
27. Macroepidemiology of Influenza Vaccination Study Group. The macro-epidemiology of influenza vaccination in 56 countries, 1997-2003. Vaccine 2005; 23:5133-5143.
28. Palache A. Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential influence of national public health policies. Vaccine 2011; 29:9459-9466.
29. WHO. Meeting report: Sixth meeting on National Influenza Centres and Influenza Surveillance for the Western Pacific and South-East Asia Regions. Hanoi, Viet Nam, 29-31 May 2011. 2011. Available at http://www.wpro.who.int/emerging_diseases/meetings/docs/6th.NIC.Meeting.Report.pdf (Accessed 20 August 2013).
30. Van Kerkhove MD, Vandemaele KA, Shinde V et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011; 8:e1001053.
31. Zaman K, Roy E, Arifeen SE et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359:1555-1564.
32. Steinhoff MC, Omer SB, Roy E et al. Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. CMAJ 2012; 184:645-653.
33. Poehling KA, Szilagyi PG, Staat MA et al. Impact of maternal immunization on influenza hospitalizations in infants. Am J Obstet Gynecol 2011; 204(6 Suppl 1):S141-S148.
34. Eick AA, Uyeki TM, Klimov A et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med 2011; 165:104-111.
35. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vazquez M. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis 2010; 51:1355-1361.
36. McNeil SA, Dodds LA, Fell DB et al. Effect of respiratory hospitalization during pregnancy on infant outcomes. Am J Obstet Gynecol 2011; 204(6 Suppl 1):S54-S57.
37. Omer SB, Goodman D, Steinhoff MC et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med 2011; 8:e1000441.
38. Anderson TP, Werno AM, Barratt K, Mahagamasekera P, Murdoch DR, Jennings LC. Comparison of four multiplex PCR assays for the detection of viral pathogens in respiratory specimens. J Virol Methods 2013; 191:118-121.
39. Hollmeyer H, Hayden F, Mounts A, Buchholz U. Review: interventions to increase influenza vaccination among healthcare workers in hospitals. Influenza Other Respir Viruses 2013; 7:604-621.
40. Hayward AC, Harling R, Wetten S et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 2006; 333:1241.
41. Burls A, Jordan R, Barton P et al. Vaccinating healthcare workers against influenza to protect the vulnerable-is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine 2006; 24:4212-4221.
42. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44.
43. Rakita RM, Hagar BA, Crome P, Lammert JK. Mandatory influenza vaccination of healthcare workers: a 5-year study. Infect Control Hosp Epidemiol 2010; 31:881-888.
44. Babcock HM, Gemeinhart N, Jones M, Dunagan WC, Woeltje KF. Mandatory influenza vaccination of health care workers: translating policy to practice. Clin Infect Dis 2010; 50:459-464.
45. Johnson JG, Talbot TR. New approaches for influenza vaccination of healthcare workers. Curr Opin Infect Dis 2011; 24:363-369.
46. Helms CM, Polgreen PM. Should influenza immunisation be mandatory for healthcare workers? Yes. BMJ 2008; 337:a2142.
47. Oshitani H, Saito R, Seki N et al. Influenza vaccination levels and influenza-like illness in long-term-care facilities for elderly people in Niigata, Japan, during an influenza A (H3N2) epidemic. Infect Control Hosp Epidemiol 2000; 21:728-730.
48. Song JY, Park CW, Jeong HW, Cheong HJ, Kim WJ, Kim SR. Effect of a hospital campaign for influenza vaccination of healthcare workers. Infect Control Hosp Epidemiol 2006; 27:612-617.
49. Lee HY, Fong YT. On-site influenza vaccination arrangements improved influenza vaccination rate of employees of a tertiary hospital in Singapore. Am J Infect Control 2007; 35:481-483.
50. Vesikari T, Knuf M, Wutzler P et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365:1406-1416.
51. de Lataillade C, Auvergne S, Delannoy I. 2005 and 2006 seasonal influenza vaccination coverage rates in 10 countries in Africa, Asia Pacific, Europe, Latin America and the Middle East. J Public Health Policy 2009;30:83-101.
52. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010:CD004876.
53. Praditsuwan R, Assantachai P, Wasi C, Puthavatana P, Kositanont U. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J Med Assoc Thai 2005; 88:256-264.
54. Isahak I, Mahayiddin AA, Ismail R. Effectiveness of influenza vaccination in prevention of influenza-like illness among inhabitants of old folk homes. Southeast Asian J Trop Med Public Health 2007; 38:841-848.
55. Salk JE. Reactions to concentrated influenza virus vaccines. J Immunol 1948; 58:369-395.
56. Cox NJ, Subbarao K. Influenza. Lancet 1999; 354:1277-1282.
57. Hampson AW. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singapore 2008; 37:510-517.
58. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-1998.
59. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Human Vaccin Immunother 2012; 8:81-88.
60. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012; 30:7443-7446.
61. Lee BY, Bartsch SM, Willig AM. Corrigendum to "The economic value of a quadrivalent versus trivalent influenza vaccine" [Vaccine 30 (2012) 7443-7446]. Vaccine 2013; 31:2477-2479.
62. Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 2012; 30:886-892.
63. Heikkinen T, Heinonen S. Effectiveness and safety of influenza vaccination in children: European perspective. Vaccine 2011; 29:7529-7534.
64. Monto AS, Ohmit SE, Petrie JG et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260-1267.
65. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 2011; 5:67-75.
66. Ohmit SE, Victor JC, Rotthoff JR et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513-2522.
67. Ohmit SE, Victor JC, Teich ER et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008; 198:312-317.
68. Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. H5N1 vaccines in humans. Virus Res 2013; Available at http://dx.doi.org/10.1016/j.virusres.2013.05.006 (Accessed 20 August 2013).
69. Hughes B, Hayden F, Perikov Y, Hombach J, Tam JS. Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses, World Health Organization, Geneva, 16-17 November 2011. Vaccine 2012; 30:6612-6622.
70. Stephenson I, Hayden F, Osterhaus A et al. Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009. Vaccine 2010; 28:3875-3882.
71. Mannino S, Villa M, Apolone G et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012; 176:527-533.
72. de Lavallade H, Garland P, Sekine T et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011; 96:307-314.
73. Girard MP, Tam JS, Pervikov Y, Katz JM. Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013. Vaccine 2013; 31:3766-3771.
74. Glezen WP. Cell-culture-derived influenza vaccine production. Lancet 2011; 377:698-700.
75. Barrett PN, Portsmouth D, Ehrlich HJ. Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development. Expert Rev Vaccines 2013; 12:395-413.
76. Barrett PN, Berezuk G, Fritsch S et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011; 377:751-759.
77. Frey S, Vesikari T, Szymczakiewicz-Multanowska A et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997-1004.
78. Ehrlich HJ, Berezuk G, Fritsch S et al. Clinical development of a Vero cell culture-derived seasonal influenza vaccine. Vaccine 2012; 30:4377-4386.
79. Corti D, Voss J, Gamblin SJ et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-856.
80. Clementi N, Criscuolo E, Castelli M, Clementi M. Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. New Microbiol 2012; 35:399-406.
81. King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 2009; 27:6589-6594.
82. ®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733-7739.
83. ® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011; 29:2272-2278.
84. Jennings LC, Smith DW, Chan PK. Report of the first Asia-Pacific Forum on antiviral treatment of influenza. Asia-Pacific Alliance for the Control of Influenza, Bangkok, 14 June 2012. Influenza Other Respi Viruses. 2013; doi: 10.1111/irv.12130.
85. Osterholm MT, Ballering KS, Kelley NS. Major challenges in providing an effective and timely pandemic vaccine for influenza a(H7N9). JAMA 2013; 309:2557-2558.